Publications by authors named "Ruby Alonso-Ramirez"

The antitumor activity of CD4(+) T cells is increasingly acknowledged in both humans and mice. The involved mechanisms have been mostly studied using transplanted tumor mouse systems. In these models, many tumor cells die at the time of implantation leading to the release of Ag in an inflammatory context contrasting with the slow and nondestructive growth of early-stage human tumors.

View Article and Find Full Text PDF

For decades Experimental Autoimmune Encephalitis (EAE) has remained as an unsurpassed multiple sclerosis (MS) animal model. C-Phycocyanin (C-Pc) has been reported to exhibit pharmacological properties that may be expected to symptomatically improve EAE and MS. However, in this paper we reveal a basic underlying mechanism that may provide a new approach to the rationale of the overall beneficial effect of this natural antioxidant.

View Article and Find Full Text PDF
Article Synopsis
  • CD6 is a glycoprotein found on most T cells and some B cells, involved in cell adhesion and immune response regulation.
  • CD6 interacts with various ligands, enhancing T cell proliferation and participating in antigen presentation, with implications in autoimmune diseases like rheumatoid arthritis and multiple sclerosis.
  • The humanized anti-CD6 monoclonal antibody T1h shows potential as an immunological regulator and anti-T/B cell treatment based on experimental and clinical data.
View Article and Find Full Text PDF

Autoreactive B cells are central in the pathogenesis of autoimmune diseases (AID) not only by producing autoantibodies but also by secreting cytokines and by presenting autoantigens. Changes in DNA methylation, histone modifications, and miRNA expression, the hallmarks of epigenetic failure, characterize B cells isolated from patients with AID, highlighting the contribution of epigenetic processes to autoreactivity. Additional evidence of epigenetic involvement in the development of B cell autoreactivity comes from in vivo and in vitro studies using DNA demethylating agents as accelerating factors or histone deacetylase inhibitors as repressing factors.

View Article and Find Full Text PDF